Europe Cyclodextrins in Pharma Market, By Type (Β Cyclodextrin, 2-Hydroxypropyl-Β-Cyclodextrin, Α Cyclodextrin, γ-Cyclodextrin, Randomly Methylated Β-Cyclodextrin, Sulfobutylether Β-Cyclodextrin and 2-Hydroxypropyl-Γ-Cyclodextrin), Structure (Cyclodextrin Conjugates, Mucoadhesive Drug Carriers, Cyclodextrin Associates, Amphiphilic Cyclodextrins and Others), Nature (Hydrophilic and Hydrophobic), Form (Solid and Liquid), Application (Drug Solubility and Dissolution, Drug Bioavailability, Drug Safety, Drug Stability and Others), Therapeutic Aareas (Pain Management, Cardiovascular Diseases, Behavioral Disorder, Cancer Therapy, Rheumatoid Arthritis, Epilepsy, Niemann Pick Disease Type C (NPC) and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.
Europe Cyclodextrins in Pharma Market Analysis and Size
Lately, the cyclodextrins in pharma market is expected to grow extensively during the forecast period 2023-2030. Cyclodextrins are extensively used in manufacturing cosmetics and personal care items such as face masks, creams, and lotions, among other things, and is projected to increase the market expansion in the upcoming years. In the meantime, the increasing popularity of dietary supplements to boost the immunity globally which is likely to increase the market expansion in the forecast period.
Data Bridge Market Research analyses a growth rate in the cyclodextrins in pharma market in the forecast period 2023-2030. The expected CAGR of cyclodextrins in pharma market is tend to be around 4.2% in the mentioned forecast period. The market was valued at USD 32.8 million in 2022, and it would grow up to USD 45.5 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Europe Cyclodextrins in Pharma Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Β Cyclodextrin, 2-Hydroxypropyl-Β-Cyclodextrin, Α Cyclodextrin, γ-Cyclodextrin, Randomly Methylated Β-Cyclodextrin, Sulfobutylether Β-Cyclodextrin and 2-Hydroxypropyl-Γ-Cyclodextrin), Structure (Cyclodextrin Conjugates, Mucoadhesive Drug Carriers, Cyclodextrin Associates, Amphiphilic Cyclodextrins and Others), Nature (Hydrophilic and Hydrophobic), Form (Solid and Liquid), Application (Drug Solubility and Dissolution, Drug Bioavailability, Drug Safety, Drug Stability and Others), Therapeutic Areas (Pain Management, Cardiovascular Diseases, Behavioral Disorder, Cancer Therapy, Rheumatoid Arthritis, Epilepsy, Niemann Pick Disease Type C (NPC) and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe
|
|
Market Players Covered
|
Cambrex Corporation (U.S.), Cayman Chemical (U.S.), Wellona Pharma (India), Wacker Chemie AG (Germany), Tocopharm Co. Limited (China), Roquette Frères (France), Midas Pharma GmbH (Germany), Ligand Pharmaceuticals Incorporated (U.S.), Cyclo Therapeutics, Inc. (U.S.), Zibo Qianhui biological technology co., ltd (China), Xi'an Deli Biochemical Industry Co., Ltd (China), Merck KGaA (Germany), Otto Chemie Pvt. Ltd. (India), VIO CHEMICALS (Switzerland), Ashland (U.S.), TCI Chemicals (India) Pvt. Ltd. (Japan)
|
|
Market Opportunities
|
|
Market Definition
Cyclodextrins are the kind of complex cyclic sugar which is made up of a macrocyclic ring of glucose subunits that is linked together by alpha-1,4 glycosidic linkages. Cyclodextrin is formed when a starch is decomposed enzymatically into simple molecules. Cyclodextrin is widely used in the pharmaceutical and chemical industries in the form of solvent component in medication delivery. Cyclodextrin is widely used to increase drug water solubility, stability, and bioavailability by encapsulating hydrophobic medicinal molecules in biological systems.
Europe Cyclodextrins in Pharma Market Dynamics
Drivers
- Increasing Consumption of Dietary Supplements
The increasing consumption of dietary supplements is projected to increase the market's growth. Excipients such as cyclodextrin are used in pharmaceutical and nutraceutical formulations. Also because of COVID-19 pandemic, physicians have prescribed a wide variety of antiviral therapeutics to patients to help them fight the virus early on. The increasing use of these medications has increased the cyclodextrin consumption, boosting market growth throughout the forecast period 2023-2030.
- Increasing investment for healthcare infrastructure
Another factor that is boosting the growth of the cyclodextrins in pharma market is the increasing healthcare expenditure that helps in improving its infrastructure. Additionally, numeorus government organizations aim to develop the healthcare infrastructure by growing their funding to influence cyclodextrins dynamics in the pharma market. Moreover, rising initiatives by private and public organizations to increase awareness will increase the demand for cyclodextrins in the pharma market. Furthermore, the huge drift of consumer behavior towards health and the rising use of cyclodextrins in renal diseases will also increase the cyclodextrins in pharma market growth.
Opportunities
- Huge Application in Drug Solubility And Dissolution
Cyclodextrins have a wide application in drug solubility and dissolution which are anticipated to dominate the market because of the presence of cyclodextrins for many administrations, such as oral, gastrointestinal, top-of-the-line drugs to increase drug efficacy. Thus, this boosts the market growth.
- Rising Adoption of Direct Tender Segment
The direct tender channel is majorly increasing the market growth since the drugs are used for the cyclodextrins in pharma that can be obtained through direct tender on reasonable price and the patients receive treatment for prolonged period of time. Therefore, this factor enhances the market growth.
Restraints/Challenges
- High Cost of Treatment
Numerous treatment methods require surgery and high-end medications that demand huge cost. The lower economic groups cannot retrieve these treatment processes. Therefore, this factor impedes the market growth since the treatment options are not feasible for all the economic groups.
- Lack of Reimbursement Policies
There is a lack of reimbursement for cyclodextrins in pharma, which are expected to restrict the market growth. Both public and private payers do not compensate majority of the treatment services. The high cost of such services vary much and there cannot be any standardization. Therefore, this factor hampers the market growth.
This cyclodextrins in pharma market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cyclodextrins in pharma market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Europe Cyclodextrins in Pharma Market Scope
The cyclodextrins in pharma market is segmented on the basis of type, structure, nature, form, application, therapeutic areas and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Β Cyclodextrin
- 2-Hydroxypropyl-Β-Cyclodextrin
- Α Cyclodextrin
- γ-Cyclodextrin
- Randomly Methylated Β-Cyclodextrin
- Sulfobutylether Β-Cyclodextrin
- 2-Hydroxypropyl-Γ-Cyclodextrin
Structure
- Cyclodextrin Conjugates
- Mucoadhesive Drug Carriers
- Cyclodextrin Associates
- Amphiphilic Cyclodextrins
- Others
Nature
- Hydrophilic
- Hydrophobic
Form
- Solid
- Liquid
Application
- Drug Solubility and Dissolution
- Drug Bioavailability
- Drug Safety
- Drug Stability
- Others
Therapeutics Area
- Pain Management
- Cardiovascular Diseases
- Behavioral Disorder
- Cancer Therapy
- Rheumatoid Arthritis
- Epilepsy
- Niemann Pick Disease Type C (NPC)
- Others
Distribution Channel
- Direct Tender
- Retail Sales
- Others
Cyclodextrins in Pharma Market Regional Analysis/Insights
The cyclodextrins in pharma market is analyzed and market size insights and trends are provided by type, structure, nature, form, application, therapeutic areas and distribution channel as referenced above.
The major countries covered in the cyclodextrins in pharma market report are Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe.
Germany leads the Europe cyclodextrins in pharma market because of the large number of companies, R & D capabilities and the increasing adoption of cyclodextrin in the pharma industry.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Europe Cyclodextrins in Pharma Market Share Analysis
The cyclodextrins in pharma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cyclodextrins in pharma market
Key players operating in the cyclodextrins in pharma market include:
- Cambrex Corporation (U.S.)
- Cayman Chemical (U.S.)
- Wellona Pharma (India)
- Wacker Chemie AG (Germany)
- Tocopharm Co. Limited (China)
- Roquette Frères (France)
- Midas Pharma GmbH (Germany)
- Ligand Pharmaceuticals Incorporated (U.S.)
- Cyclo Therapeutics, Inc. (U.S.)
- Zibo Qianhui biological technology co., ltd (China)
- Xi'an Deli Biochemical Industry Co., Ltd (China)
- Merck KGaA (Germany)
- Otto Chemie Pvt. Ltd. (India)
- VIO CHEMICALS (Switzerland)
- Ashland (U.S.)
- TCI Chemicals (India) Pvt. Ltd. (Japan)
SKU-